Key result
AAV8-LDLr gene therapy lowers cholesterol ~82% and prevents HFpEF in diabetic mice.
Why the study?
Hypercholesterolemia may be causally linked to HFpEF, prompting the development of a hypercholesterolemic type 2 diabetes HFpEF model to test whether cholesterol-lowering AAV8-mediated LDLr gene transfer prevents HFpEF.
Does AAV8-LDLr gene transfer prevent HFpEF in a mouse model of obesity and type 2 diabetes?
Does AAV8-LDLr gene transfer prevent HFpEF in a mouse model of obesity and type 2 diabetes?
Cholesterol-lowering gene therapy prevents structural remodeling and HFpEF in a diabetic mouse model, suggesting hypercholesterolemia may causally contribute to HFpEF.
Supports causal role of hypercholesterolemia in diabetic HFpEF; hypothesis-generating and requires human validation before clinical consideration.
Hypercholesterolemia may be causally related to heart failure with preserved ejection fraction (HFpEF). We aimed to establish a HFpEF model associated with hypercholesterolemia and type 2 diabetes mellitus by feeding a high-sucrose/high-fat (HSHF) diet to C57BL/6J low-density lipoprotein receptor (LDLr)−/− mice. Secondly, we evaluated whether cholesterol-lowering adeno-associated viral serotype 8 (AAV8)-mediated LDLr gene transfer prevents HFpEF. AAV8-LDLr gene transfer strongly (p < 0.001) decreased plasma cholesterol in standard chow (SC) mice (66.8 ± 2.5 mg/dl versus 213 ± 12 mg/dl) and in HSHF mice (84.6 ± 4.4 mg/dl versus 464 ± 25 mg/dl). The HSHF diet induced cardiac hypertrophy and pathological remodeling, which were potently counteracted by AAV8-LDLr gene transfer. Wet lung weight was 19.0% (p < 0.001) higher in AAV8-null HSHF mice than in AAV8-null SC mice, whereas lung weight was normal in AAV8-LDLr HSHF mice. Pressure–volume loop analysis was consistent with HFpEF in AAV8-null HSHF mice and showed a completely normal cardiac function in AAV8-LDLr HSHF mice. Treadmill exercise testing demonstrated reduced exercise capacity in AAV8-null HSHF mice but a normal capacity in AAV8-LDLr HSHF mice. Reduced oxidative stress and decreased levels of tumor necrosis factor-α may mediate the beneficial effects of cholesterol lowering. In conclusion, AAV8-LDLr gene therapy prevents HFpEF.
No takes yet. Share an insight, caveat, or question.
Aboumsallem et al. (2019) studied Heart failure with preserved ejection fraction (HFpEF). AAV8-LDLr gene transfer vs. AAV8-null control vector was evaluated on Plasma cholesterol in HSHF mice (decreased by 81.8%, p=<0.001). AAV8-LDLr gene therapy decreased plasma cholesterol by 81.8% and prevented heart failure with preserved ejection fraction in obese type 2 diabetic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: